Advanced search×

Formulation and evaluation of metformin oro-dispersible tablets.

Munish M Kamboj, Surinder S Goyal, Pankaj P Rakha, Gitika G Arora, Harish H Dureja, and Manju M Nagpal

Acta Pol Pharm 68(5):717-23 (2011) PMID 21928717

The purpose of this research was to develop oro-dispersible tablets of metformin by direct compression method using super disintegrants approach, effervescent approach and sublimation approach. Powder blend was evaluated for angle of repose, bulk density, tapped density, compressibility index, Hausner's ratio and bulkiness. The tablets were evaluated for uniformity of weight, friability test, hardness, drug content, wetting time, water absorption ratio, disintegration time and in vitro dissolution. Higher dissolution rates were achieved in selected batches (A5, B4, C4, and D3) as compared to marketed product. Batch C4 prepared by effervescent approach was found to have the least disintegration time and maximum in vitro dissolution profile.

Version: za2963e q8zae q8zb5 q8zc1 q8zda q8ze6 q8zf8 q8zg0
Buy PDF

Similar articles you may find interesting…

  1. The cytotoxicity evaluation of magnetic iron oxide nanoparticles on human aortic endothelial cells.
    Gaoyuan Ge, Hengfang Wu, and Di Yang

    Nanoscale Res Lett 8(1):215 (2013) PMID 23647620

    We evaluated the cytotoxicity effect of dimercaptosuccinic acid-coated iron oxide (DMSA-Fe2O3) using cultured human aortic endothelial cells (HAECs). Our results showed that DMSA-Fe2O3 in the culture medium could be absorbed into HAECs, and dispersed in the cytoplasm. The cytotoxicity effect of DMSA...
    PDF not found
  2. Design and physicochemical characterization of poly(amidoamine) nanoparticles and the toxicological evaluation in human endothelial cells: a...
    Grégory Coué, Christian Freese, and Johan F J Engbersen

    J Biomater Sci Polym Ed 24(8):957-71 (2013) PMID 23647251

    We investigated nanoparticles formulated by self-assembly of a biodegradable poly(amidoamine) (PAA) and a fluorescently labeled peptide, in their capacity to internalize in endothelial cells and deliver the peptide, with possible applications for brain drug delivery. The nanoparticles were character...
    Buy PDF
  3. Study Design and Rationale of a Dose-Ranging Trial of LX4211, a Dual Inhibitor of SGLT1 and SGLT2, in Type 2 Diabetes Inadequately Controlle...
    Pablo Lapuerta, Julio Rosenstock, and Arthur Sands

    Clin Cardiol (2013) PMID 23630033

    We describe the design and rationale of a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of LX4211 in subjects with type 2 diabetes mellitus who have inadequate glycemic control on metformin monotherapy. The primary endpoi...
    Buy PDF